Management of Acute Complications of Targeted Therapy in Patients With Cancer: A Review of Cases Managed in ICU

Pistone, Aureliano; Durieux, Valérie; Grigoriu, Bogdan; Meert, Anne-Pascale

doi:10.1177/0885066618787788

Cited by 10 publications

(2 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These studies were performed before the ASCO recommendations were published, and before the advent of new oncological approaches, such as immunotherapy. Targeted therapies and hormonal therapies are rarely considered as aggressive cancer care (ACC), but they have been shown to be associated with deleterious side effects, and have a negative impact on patient quality of life 18–20. Therefore, there is a need to re-assess the current situation to obtain an up-to-date picture of EoL practices.…”

Section: Introductionmentioning

confidence: 99%

Duration of palliative care involvement and cancer care aggressiveness near the end of life

Monier

Chrusciel²,

Ecarnot

et al. 2020

BMJ Support Palliat Care

View full text Add to dashboard Cite

ObjectivesPrevious studies have found an association between aggressive cancer care and lower quality end of life. Despite international recommendations, late or very late referral to palliative care seems frequent. This study aimed to evaluate the association between the duration of involvement of a palliative care team (PCT), and aggressive cancer care, and to identify factors associated with aggressive cancer care.MethodsWe performed an observational retrospective study in a single academic teaching hospital. In total, 561 inpatients with solid tumours or haematological malignancies were included. Patients followed by a PCT for at least 1 month before death were classified in the palliative care group. Aggressive cancer care was defined as: hospitalisations and/or a new line of chemotherapy within the last month of life, location of death, the use of chemotherapy in the last 2 weeks and hospice admissions within the last 3 days of life.ResultsAmong the 561 patients, 241 (43%) were referred to the PCT; 89 (16%) were followed by the PCT for a month or more before death. In the last 2 weeks of life, 124 (22%) patients received chemotherapy, 110 (20%) died in an acute care unit. At least one criterion of aggressive cancer care was found in 395 patients overall (71%). Aggressive cancer care was significantly less frequent when the PCT referral occurred >1 month before death (p<0.0001).ConclusionMore studies are needed to understand reasons for late referrals despite international recommendations encouraging integrative palliative care.Ethics approvalThe study was approved by the Grenoble Teaching Hospital ethics committee, and by the CNIL (French national commission for data privacy; Commission Nationale de l’Informatique et des Libertés) under the number 1987785 v 0. Due to ethical and legal restrictions, data are only available on request.

show abstract

Section: Introductionmentioning

confidence: 99%

Duration of palliative care involvement and cancer care aggressiveness near the end of life

Monier

Chrusciel²,

Ecarnot

et al. 2020

BMJ Support Palliat Care

View full text Add to dashboard Cite

show abstract

“…Une revue de littérature [20] a mis en évidence que la pneumopathie interstitielle (ILD ou Interstitial Lung Disease) est le principal effet secondaire pulmonaire grave amenant les patients en réanimation. C'est essentiellement lié au crizotinib mais d'autres molécules comme le géfitinib et l'erlotinib induisent une ILD dans 0,8 % des patients traités, avec une prédominance chez les patients d'origine asiatique.…”

Section: Complications Sévères Des Thérapies Cibléesunclassified

Complications sévères des traitements systémiques du patient cancéreux thoracique (complications hors infections et urgences respiratoires)

Berghmans,

Brandão,

Ilzkovitz

et al. 2024

Revue des Maladies Respiratoires

View full text Add to dashboard Cite

Qingjie Fuzheng Granule suppresses lymphangiogenesis in colorectal cancer via the VEGF-C/VEGFR-3 dependent PI3K/AKT pathway

Huang

Gui

et al. 2021

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

Management of Acute Complications of Targeted Therapy in Patients With Cancer: A Review of Cases Managed in ICU

Abstract: The side effects induced by targeted therapies may be fatal but are generally potentially reversible. The main treatment includes stopping current therapy and symptomatic management. Treatment rechallenge should be discussed on a case-by-case basis.

Cited by 10 publications

References 62 publications

Duration of palliative care involvement and cancer care aggressiveness near the end of life

Duration of palliative care involvement and cancer care aggressiveness near the end of life

Complications sévères des traitements systémiques du patient cancéreux thoracique (complications hors infections et urgences respiratoires)

Qingjie Fuzheng Granule suppresses lymphangiogenesis in colorectal cancer via the VEGF-C/VEGFR-3 dependent PI3K/AKT pathway

Contact Info

Product

Resources

About